PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26026F0017Uptravi 800mcg TABS — Actelion Pharmaceuticals Us, Inc

Actelion Pharmaceuticals Us, Inc holds $5.4M across 106 federal awards, concentrated at Department of Veterans Affairs (VA). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

260-Network Contract Office 20 (36C260)

Awarding office

Actelion Pharmaceuticals Us, Inc

Recipient

Sep 30, 2026

PoP end

$407K

Obligated

$407K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Actelion Pharmaceuticals Us, Inc — $90

Contract facts

Federal

Contract number36C26026F0017

Also listed as36C260-26-F-0017

Also listed as36F79724D0159-36C26026F0017

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentActelion Pharmaceuticals Us, Inc

CAGE33TN9

UEIH5BMHLMMNA28

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79724D0159

Place of performanceMEMPHIS TN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2025

PoP end (current)Sep 30, 2026

Obligated$407K

Current value$407K

Potential value$407K

UPTRAVI 800MCG TABS is a federal award for 260-Network Contract Office 20 (36C260) held by Actelion Pharmaceuticals Us, Inc. Estimated value $407K ($407K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: MEMPHIS TN.

Recompete timing

Public

● Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Actelion Pharmaceuticals Us, Inc — $5.4M obligated across 106 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($5.4M) · all agencies

Department of Veterans Affairs (VA)$3.2M · 59%Department of Justice (DOJ)$2.2M · 41%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26026F0017?

36C26026F0017 (Uptravi 800mcg TABS) is a 260-Network Contract Office 20 (36C260) award with a potential value of $407K, currently held by Actelion Pharmaceuticals Us, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-26-F-0017?

36C260-26-F-0017 is the dashed form of PIID 36C26026F0017 (Uptravi 800mcg TABS), held by Actelion Pharmaceuticals Us, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26026F0017?

260-Network Contract Office 20 (36C260) awarded 36C26026F0017 to Actelion Pharmaceuticals Us, Inc (potential $407K).

Who is the incumbent on 36C26026F0017?

Actelion Pharmaceuticals Us, Inc is the incumbent with $5.4M across 106 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Actelion Pharmaceuticals Us, Inc’s 36C26026F0017 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Oct 1, 2025